Glenmark Pharmaceuticals (India) holds 0 active US FDA Type II Drug Master Files and 4 inactive, has DMF or CEP filings on record for 3 active ingredients and is linked to 4 FDA-registered manufacturing sites. 38 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Glenmark Pharmaceuticals: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/glenmark-pharmaceuticals

Overview

Glenmark Pharmaceuticals is a global innovative pharmaceutical company committed to enriching lives worldwide. Headquartered in Mumbai, India, the company focuses on creating new, affordable therapies in areas like dermatology, respiratory, and oncology.

Core services & business areas

ManufacturingResearch and DevelopmentQuality ControlRegulatory AffairsMarketingSalesPharmaceutical ManufacturingSales and Marketing

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Glenmark Pharmaceuticals holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Glenmark Pharmaceuticals holds 0 active (4 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • PALONOSETRON HYDROCHLORIDEInactive2010-11-19
  • TELMISARTANInactive2005-09-12
  • SIMVASTATINInactive2004-12-30
  • MFG SITE FACILITIES OPERATING PROCEDURES AND PERSONEL FOR SATPUR NASIK INDIA SITEInactive1999-12-25

Registered manufacturing sites (4)

Physical sites registered with the US FDA and resolved to Glenmark Pharmaceuticals, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

38 FDA enforcement records linked to this company.

  • warning_letter2025-07-11

    FDA Warning Letter (drug product)

  • 4832025-02-14

    Investigations of discrepancies, failures

  • 4832025-02-14

    Cleaning / Sanitizing / Maintenance

  • 4832025-02-14

    Approve or reject procedures or specs

  • 4832025-02-14

    Test methods

  • 4832025-02-14

    Mfg / Processing Operations Area

  • warning_letter2022-11-22

    FDA Warning Letter (drug product)

  • 4832022-06-22

    Failure to meet specifications

  • 4832022-06-22

    Procedures not in writing, fully followed

  • 4832022-06-22

    Absence of Written Procedures

  • 4832022-06-22

    input/output verification

  • 4832022-06-22

    Investigations of discrepancies, failures

  • 4832022-06-22

    Cleaning / Sanitizing / Maintenance

  • 4832022-05-20

    Scientifically sound laboratory controls

  • 4832022-05-20

    Extent of discrepancy, failure investigations

  • 4832022-05-20

    Absence of Written Procedures

  • 4832022-05-20

    Equipment Design, Size and Location

  • 4832022-05-20

    Prepared for each batch, include complete information

  • warning_letter2019-10-03

    FDA Warning Letter (drug product)

  • 4832019-03-15

    Valid stability test methods

  • 4832019-03-15

    Testing and release for distribution

  • 4832019-03-15

    Cleaning / Sanitizing / Maintenance

  • 4832019-03-15

    Approve or reject procedures or specs

  • 4832019-03-15

    Scientifically sound laboratory controls

  • 4832017-11-11

    Investigations of discrepancies, failures

  • 4832017-11-11

    Absence of Written Procedures

  • 4832017-11-11

    Procedures not in writing, fully followed

  • 4832017-11-11

    Computer control of master formula records

  • 4832017-11-11

    Training--operations, GMPs, written procedures

  • 4832017-11-11

    Records reviewed annually

  • 4832017-11-11

    Complaint Investigation/Follow-Up Findings

  • 4832016-02-26

    Written warehousing procedures established/followed

  • 4832016-02-26

    Computer control of master formula records

  • 4832016-02-26

    Control procedures fail to include the following

  • 4832013-07-19

    Written Procedures Not Followed

  • 4832013-07-19

    Complaint Handling Procedure

  • 4832013-07-19

    Investigations of discrepancies, failures

  • 4832013-07-19

    Procedures for non-sterile drug products

For suppliers

Is this Glenmark Pharmaceuticals?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.